TKToru Kaneko

Toru Kaneko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Toru Kaneko has a total of 95 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Early precut is useful for difficult bile duct cannulation, particularly in cases with long oral protrusion

    by Toru Kaneko, Mitsuhiro Kida, Takahiro Kurosu, Gen Kitahara, Tomohiro Betto, Yutaro Saito, Shiori Koyama, Nao Nomura, Chika Kusano

    BACKGROUND Endoscopic retrograde cholangiopancreatography involves selective bile duct cannulation, which is often challenging and associated with complications. In difficult cannulation cases, early precutting is frequently used. However, its efficacy and optimal indications require further evaluation. AIM To evaluate the efficacy and safety of early precut (EP) in difficult bile duct cannulation. METHODS This retrospective analysis of endoscopic retrograde cholangiopancreatography procedures was performed for bile duct cannulation in patients with naive papillae who required advanced cannulation techniques (ACTs). These patients were admitted between April 2020 and March 2024 and were analyzed for risk factors, success rates, and complications. Outcomes were compared between the EP group and the conventional other ACTs group, with a focus on cases with oral protrusion large (oral protrusion-L). RESULTS The need for ACTs was identified as an independent risk factor for complications [odds ratio (OR) = 5.4; 95% confidence interval: 1.887-15.53]. Malignant biliary strictures (OR = 2.58) and oral protrusion-L (OR = 2.77) were also identified as independent risk factors for requiring ACTs. The EP group had a significantly higher second-line cannulation success rate (97.9% vs 73.2%, P = 0.001) and lower complication rate (8.3% vs 39.0%, P = 0.001) than the other ACTs group. Additionally, similar benefits were observed in the oral protrusion-L cases. CONCLUSION This study provides compelling evidence that EP is a viable alternative and a superior strategy in cases requiring ACTs, particularly oral protrusion-L.


  • Incidence of Cholecystitis After Endoscopic Biliary Drainage Using a Low Axial Force Covered Self‐Expandable Metallic Stent in Patients With Malignant Distal Biliary Obstruction: A Multicenter Prospective Study

    by Naoki Minato, Kosuke Okuwaki, Masafumi Watanabe, Jun Woo, Takaaki Matsumoto, Masayoshi Tadehara, Toru Kaneko, Junro Ishizaki, Tomohisa Iwai, Hiroshi Imaizumi, et al.

    Background and Aim: No prospective studies have verified the incidence of cholecystitis in patients using the covered self‐expandable metallic stent. In this study, we aimed to investigate the incidence of cholecystitis and its risk factors after low axial force covered self‐expandable metallic stent placement for malignant distal biliary obstruction.Methods: This multicenter prospective study included patients diagnosed with unresectable distal biliary obstruction between November 2019 and October 2022 who underwent low axial force covered self‐expandable metallic stent placement.Results: The technical success in the 93 analyzed patients was 100% and clinical success was 98.9%. The 70‐mm covered self‐expandable metallic stent was the most used in 53 patients (57.0%), followed by the 80‐mm type in 27 patients (29.0%), 60‐mm type in 12 patients (12.9%), and 50‐mm type in 1 patient (1.1%). Cholecystitis after covered self‐expandable metallic stent placement occurred in six patients (6.5%). The median time to onset was 46 days (range, 16–315 days), with 1 case in the early stage and five cases in the late stage. There was one mild case, one moderate case, and four severe cases. The presence of tumor involvement at the orifice of the cystic duct was identified as an independent risk factor (odds ratio, 17.0; 95% confidence interval, 1.5–195.1; p = 0.023).Conclusions: The presence of tumor involvement at the orifice of the cystic duct was an independent risk factor for the development of cholecystitis after low axial covered self‐expandable metallic stent placement.Trial registration: University Hospital Medical Information Network (UMIN) (http://www.umin.ac.jp, registration number: UMIN 000038209)


  • Pancreaticojejunostomy with Forward-Viewing Echoendoscope

    by Mitsuhiro Kida, Tomohisa Iwai, Rikiya Hasegawa, Toru Kaneko, Kosuke Okuwaki

  • Open Access

    Outcomes of Interferon-free Treatment of Hepatitis C Virus Infection Seven Years after Approval and Problems with Drop out during and after Treatment: A Retrospective, Single-center Study

    by Masaaki Watanabe, Hiroaki Yokomori, Gen Kitahara, Kazuho Uehara, Shiori Koyama, Tsutomu Minamino, Toshikazu Otsuka, Toru Kaneko, Kumiko Tahara, Mitsuhiro Kida

    Objective This retrospective, single-center study assessed the effects of interferon (IFN)-free treatment of HCV infection, which has been approved for seven years; calculated the incidence of hepatocellular carcinoma (HCC) after achieving a sustained virologic response (SVR); and elucidated problems with follow-up for surveillance of post-SVR HCC, particularly the impact of the coronavirus disease 2019 (COVID-19) pandemic. Methods and Patients We summarized the SVR achievement rate of 286 HCV-infected patients who received 301 IFN-free treatments and analyzed the cumulative incidence of initial HCC and the cumulative continuation rate of follow-up after SVR in the 253 patients who achieved SVR and did not have a history of HCC. Results Among 286 patients who received IFN-free treatments, 14 dropped out, and the 272 remaining patients achieved an SVR after receiving up to third-line treatment. Post-SVR HCC occurred in 18 (7.1%) of the 253 patients without a history of HCC, with a cumulative incidence at 3 and 5 years after SVR of 6.6% and 10.0%, respectively; the incidence of cirrhosis at those time points was 18.2% and 24.6%, respectively.Of the 253 patients analyzed, 58 (22.9%) discontinued follow-up after SVR. Patients who had no experience with IFN-based therapy tended to drop out after SVR. Notably, the number of dropouts per month has increased since the start of the pandemic. Conclusion Currently, IFN-free treatment is showing great efficacy. However, the incidence of HCC after SVR should continue to be monitored. In this study, the COVID-19 pandemic did not affect treatment outcomes, but it may affect surveillance for post-SVR HCC.


  • Open Access

    Cholecystitis after Placement of Covered Self-Expandable Metallic Stents in Patients with Distal Malignant Biliary Obstructions

    by Masafumi Watanabe, Kosuke Okuwaki, Jun Woo, Mitsuhiro Kida, Hiroshi Imaizumi, Tomohisa Iwai, Hiroshi Yamauchi, Toru Kaneko, Rikiya Hasegawa, Takahiro Kurosu, et al.

    Background/Aims: Cholecystitis can occur after the placement of covered self-expandable metallic stents for distal malignant biliary obstructions. We aimed to identify risk factors for cholecystitis following covered self-expandable metallic stent placement.Methods: We investigated risk factors related to cholecystitis following covered self-expandable metallic stent placement in 118 patients with distal malignant biliary obstructions between January 1, 2015 and April 30, 2019. Endoscopic assessments and tumor invasion to the arteries feeding the gallbladder were determined by a pancreaticobiliary endoscopist and a radiologist, respectively.Results: The median patient age was 72 years (men, 61.0%). The flow of the contrast agent into the gallbladder and tumor involvement in the orifice of the cystic duct were observed in 35 (29.7%) and 35 (29.7%) patients, respectively. During the observation period (median, 179 days), cholecystitis occurred in 18 (15.3%) patients. Multivariate analysis revealed the flow of the contrast agent into the gallbladder (p=0.023) and tumor involvement in the orifice of the cystic duct (p=0.005) as significant independent risk factors associated with cholecystitis.Conclusions: The flow of the contrast agent into the gallbladder and tumor involvement in the orifice of the cystic duct are potential independent risk factors for cholecystitis following the placement of covered self-expandable metallic stents. A follow-up prospective study is warranted to validate their influence.


  • Open Access

    New image‐processing technology for endoscopic ultrasound‐guided fine‐needle aspiration biopsy specimen evaluation in patients with pancreatic cancer

    by Kosuke Okuwaki, Hiroshi Imaizumi, Mitsuhiro Kida, Hironori Masutani, Masafumi Watanabe, Kai Adachi, Masayoshi Tadehara, Akihiro Tamaki, Tomohisa Iwai, Hiroshi Yamauchi, et al.

    Objectives: We evaluated the usefulness of a newly developed system with which the total amount of whitish cores in endoscopic ultrasound‐guided fine‐needle aspiration biopsy (EUS‐FNAB) samples is automatically calculated (automated multiband imaging system [AMUS]).Methods: From 30 prospectively enrolled patients suspected of having pancreatic cancer, four EUS‐FNAB specimens per patient were obtained. Following AMUS calculations, two specimens were prepared after stereomicroscopy‐guided manual division into whitish and reddish sections (isolation group), and the other two were prepared without such division (no‐isolation group). The relation of the AMUS results pertaining to the length of the manually measured whitish cores (stereo‐microscopically visible white core [SVWC]) and the sample suitability for pathologic evaluation were analyzed.Results: Histological diagnostic accuracy was 90%; median SVWC length, 14 mm; and median area of whitish core calculated using the AMUS, 13 mm2. The SVWC length correlated with whitish core amount (ρ = 0.83, p < 0.01) and adequacy score (ρ = 0.50, p < 0.01). The whitish core amount correlated with the adequacy score (ρ = 0.40, p < 0.01). The area under the receiver‐operating characteristic curve calculated for whitish core amount with respect to the histological diagnosis was 0.84 (p < 0.01; cutoff ≥ 8 mm2, sensitivity 92.5%). Subgroup analysis (isolation vs. no‐isolation group) revealed no significant between‐group differences in the median histological adequacy (p = 0.27) or tumor cell content ratio (p = 0.28). The median scores for degree of blood contamination were significantly lower in the isolation group than in the no‐isolation group (p < 0.01).Conclusion: AMUS is a simple on‐site verification procedure for determining the appropriate sampling tissue quantity for high diagnostic accuracy.


  • Histopathological comparison of aspiration and biopsy needles in endoscopic ultrasound‐guided tissue acquisition in patients with subepithelial lesions

    by Masafumi Watanabe, Kosuke Okuwaki, Mitsuhiro Kida, Masayoshi Tadehara, Kai Adachi, Hironori Masutani, Akihiro Tamaki, Hiroshi Imaizumi, Tomohisa Iwai, Hiroshi Yamauchi, et al.

    Background Information on whether a fine‐needle biopsy (FNB) needle can improve histopathological specimen quality or the amount of core tissue collected in the diagnosis of subepithelial lesions (SELs) remains insufficient. In this study, we aimed to compare the procedure outcomes and adequacy of histopathological specimens of fine‐needle aspiration (FNA) and FNB needles in endoscopic ultrasound‐guided tissue acquisition (EUS‐TA) using sample isolation processing by stereomicroscopy (SIPS) in patients with SELs. Methods We performed a retrospective comparison of SEL cases registered in two previously conducted prospective studies. Of 61 cases, we identified 56 cases of SELs that involved the muscularis propria layer. Of these, 27 patients who underwent EUS‐TA using a 22‐gauge FNA needle between July 2016 and December 2017, and 29 patients who underwent the procedure using a 22‐gauge FNB needle between March 2018 and January 2019 were included in the FNA and FNB group, respectively. Results Patient background characteristics did not differ between the groups. The technical success rate was 100% in both groups. The median adequacy score was significantly higher in the FNB group than in the FNA group (P < .01). The histological diagnosis showed no significant difference in the accuracy rate between the groups. Conclusions In EUS‐TA using the SIPS procedure to target SELs derived from the muscularis propria layer, FNB needles collect more core tissues and significantly improve histopathological specimen quality compared with FNA needles. When combined with SIPS, a high tissue diagnosis rate may be obtained regardless of the type of puncture needle used.


  • Nafamostat Mesylate is Not Effective in Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis

    by Takaaki Matsumoto, Kosuke Okuwaki, Hiroshi Imaizumi, Mitsuhiro Kida, Tomohisa Iwai, Hiroshi Yamauchi, Toru Kaneko, Rikiya Hasegawa, Hironori Masutani, Masayoshi Tadehara, et al.

    Background Endoscopic retrograde cholangiopancreatography (ERCP) is associated with complications such as post-ERCP pancreatitis (PEP). Protease inhibitors, including nafamostat mesylate (NM), have been evaluated for prophylaxis against PEP. Aim We describe the first multicenter randomized controlled trial assessing the prophylactic efficacy of NM against PEP. Methods In this multicenter prospective study, we aimed to enroll 800 patients aged ≥ 20 years with a planned ERCP between December 2012 and March 2019. The primary outcome was the incidence and severity of PEP in patients who did not receive NM (non-NM) versus those who did (NM; 20 mg). Secondary outcomes included the incidence of PEP by NM initiation (pre- and post-ERCP), risk factors for PEP, and NM-related adverse events. Results Only 441 of the planned 800 patients were enrolled (non-NM: n = 149; NM: n = 292 [pre-ERCP NM: n = 144; post-ERCP NM: n = 148]). Patient characteristics were balanced at baseline with no significant differences between groups. PEP occurred in 40/441 (9%) patients (non-NM: n = 15 [10%]; NM: n = 25 [9%]), including 17 (12%) and eight (8%) in the pre-ERCP and post-ERCP NM groups, respectively. In the NM group, the incidence of PEP was lower in the low-risk group than in the high-risk group. Pancreatic injection and double-guidewire technique were independent risk factors for PEP. NM-related adverse events of hyperkalemia occurred in two (0.7%) patients. Conclusions We found no evidence for the prophylactic effect of NM against PEP, regardless of the timing of administration; however, further studies are needed.


  • A clinical trial to assess the feasibility and efficacy of nab-paclitaxel plus gemcitabine for elderly patients with unresectable advanced pancreatic cancer

    by Rikiya Hasegawa, Kosuke Okuwaki, Mitsuhiro Kida, Hiroshi Yamauchi, Yusuke Kawaguchi, Takaaki Matsumoto, Toru Kaneko, Eiji Miyata, Kazuho Uehara, Tomohisa Iwai, et al.

    The efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-PTX) plus gemcitabine (GEM) in elderly Japanese patients with pancreatic cancer remain unclear. Therefore, we prospectively investigated the tolerability and efficacy of nab-PTX + GEM in Japanese patients aged ≥ 75 years with non-curatively resectable pancreatic cancer. We treated eligible patients (n = 27) with nab-PTX + GEM until disease progression, appearance of adverse events, or withdrawal of consent. The primary endpoints included adverse events as well as dosing- and survival-related parameters. The rates of 2-cycle completion were 48.1% for nab-PTX and 55.6% for GEM; the relative dose intensities for the 7th (median) treatment cycle were 65.1% and 74.1%, respectively, whereas the dose-reduction rates were 81.5% and 48.1%, respectively. Grade 3 or higher hemotoxicity was observed in 14 of 27 subjects (51.9%); moreover, 22% experienced grade ≥ 3 peripheral nerve disorder and 1 patient (3.7%) died owing to chemotherapy-related interstitial pneumonia. The disease control rate was 92.6% (25/27), while the median progression-free and overall survival times were 7 and 10.3 months, respectively. The nab-PTX + GEM regimen is as efficacious in elderly patients who meet certain criteria as it is in previously reported non-elderly patients. The regimen is feasible with appropriate dose adjustments and attention to adverse events. Clinical trial registration number: UMIN000018907.


  • A Patient with a 10-mm Solid Pseudopapillary Neoplasm of the Pancreas in whom Contrast-enhanced Endoscopic Ultrasonography was Useful for Diagnosis

    by Masafumi Watanabe, Kosuke Okuwaki, Mitsuhiro Kida, Kai Adachi, Masayoshi Tadehara, Seigo Nakatani, Kazuho Uehara, Hironori Masutani, Yusuke Kawaguchi, Eiji Miyata, et al.

    The patient was a 46-year-old woman. CT and MRI revealed a mass, 10-mm in diameter, located in the uncinate process of the pancreas. The qualitative diagnosis was difficult. On contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) , a papillary solid region in the tumor showed contrast enhancement similar to that of the surrounding normal pancreatic parenchyma in the early phase. The contrast with an anechoic region was clearly depicted. A solid pseudopapillary neoplasm of the pancreas (SPN) was suspected, and a pylorus-preserving pancreatoduodenectomy was performed. The pathological diagnosis including the results of immunohistochemistry was an SPN. Even if the tumor diameter is small, CH-EUS can provide an evaluation of blood flow and clearer contrast on opacified images and is therefore considered a useful diagnostic modality.